About Nevakar
Nevakar is a Healthcare company based in New York (United States) founded in 2015 by Navneet Puri. Drug repositioning is conducted in injectable and ophthalmic sectors. Nevakar has raised $71.09 million across 5 funding rounds from investors including Oxford Finance and H.I.G. Capital. Its chief executive, as recorded, is George Zorich. Its Indian entity Nevakar India Private Limited reported revenue of ₹1.77 Cr. Nevakar offers products and services including NVK002. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its competitors include Annexon, Aldeyra and Gyroscope; 2 of its 3 listed competitors have raised funding.
Company details
Nevakar was established in 2015 in New York, United States, within the pharmaceutical industry. Focus is placed on repositioning FDA-approved molecules to address unmet clinical and commercial needs. Operations involve the creation of novel formulations, improved packaging designs, and alternative drug delivery methods, primarily for injectable and ophthalmic applications. The company is led by founder Navneet Puri and CEO George Zorich.
- Headquarters New York, United States
- Founders Navneet Puri
- SectorsHealthcare
- Website nevakar.com
- Social LinkedIn
- Legal Name Nevakar India Private Limited
- Date of Incorporation 06 Jan, 2020
- Jurisdiction Thane, Maharashtra, India
- Indian entity revenue₹1.77 Cr
FY 2025 · -21% YoY
- Indian entity net profit₹22.3 Lakh
FY 2025 · 13% margin
- Indian entity EBITDA₹30.6 Lakh
FY 2025 · 17% margin
- Total Equity Funding$71.09M (USD)
in 5 rounds
- Latest Funding Round$4.59M (USD), Series C
Aug 2023
- InvestorsOxford Finance
& 1 more
Associated legal entities of Nevakar
Nevakar operates through Nevakar India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Nevakar India Private Limited CIN U93090MH2020FTC335503 | Active | 06 Jan 2020 | Thane, Maharashtra | ₹1.8 Cr | 2 | View details |
Products & Services of Nevakar
Nevakar offers a comprehensive portfolio of products and services, including NVK002.
Drug for treating refractive errors through regulatory applications.
Funding Insights of Nevakar
Nevakar has successfully raised a total of $71.09M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $4.59 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $71.09M
- Total Rounds 5
- Last Round Series C — $4.59M
- First Round $11.5M
(Jun 2016)
- Investors Count 2
All 5 funding rounds of Nevakar with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $4.59M | Series C | – | – | – |
| Oct 2019 | $17.5M | Debt – Conventional | – | – | |
| Nov 2018 | $30M | Debt – Conventional | – | – | |
| Jul 2016 | $55M | Series B | – | – | – |
| Jun 2016 | $11.5M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Nevakar
Nevakar has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Oxford Finance and H.I.G. Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Private equity capital is invested in small and mid-sized businesses. | higcapital.com | Miami, United States |
Investor details for Nevakar
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Nevakar India Private Limited (Nevakar)
Nevakar India Private Limited is the primary company behind Nevakar. The board of Nevakar India Private Limited currently have 2 directors; the longest-serving is Partha Pratim Mandal, appointed in 2020. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Partha Pratim Mandal DIN 00018097 | Director | 05 Nov 2020 | 5 yrs 11 mo | Nevakar India Private Limited |
| Rahul Agarwalla DIN 07988640 | Additional Director | 24 Jul 2025 | 1 yr 3 mo | Nevakar India Private Limited |
People of Nevakar
24 people are tracked at Nevakar (9 in leadership, 4 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Navneet Puri | Founder | Leadership |
George Zorich | CEO | Leadership |
Kumaresh Soppimath | Chief Scientific Officer | Leadership |
Beshoy Nan | Associate Director Quality And Compliance | Leadership |
Tushar Hingorani | Head Of R & D | Leadership |
Eric Lang | CMO | Leadership |
Jon Cammack | Chief Quality & Compliance Officer | Leadership |
Julien Roche | Vice President Operations Management | Leadership |
Nithila Duraisamy | Vice President- Head Of Regulatory Affairs | Leadership |
George S. Zorich | CEO And Chairman Of The Board | Board & advisors |
Ram Potti | Board Member | Board & advisors |
Joseph M. Mahady | Board Member | Board & advisors |
Robert J. Spiegel | Board Member | Board & advisors |
Beatrice Larrieux | Associate Manager, Administrative & AP | Team |
Reema Puri | SVP, HR | Team |
John Kappelhof | SVP, Program Management | Team |
Harshil Jain | Associate Principal Scientist | Team |
Rajendra Kankati | Principal Scientist/ad/project Lead | Team |
Jun Liu | Research Scientist | Team |
Dattaji Deshmukh | Quality Professional | Team |
4 more people are available in the full profile.
Complete people profiles for Nevakar
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Nevakar
Figures of Nevakar India Private Limited, the primary company behind Nevakar, for FY 2025. Revenue was ₹1.77 Cr (-21% year on year). Net profit was ₹22.3 Lakh (13% margin). EBITDA was ₹30.6 Lakh (17% margin). Revenue has grown at a compounded annual rate of -13% over three years.
- ₹1.77 CrRevenue · FY 2025 · -21% YoY
- ₹22.3 LakhNet profit · 13% margin
- ₹30.6 LakhEBITDA · 17% margin
- ₹3.5 LakhPaid-up capital
- -13%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Nevakar India Private Limited are on its company page.
Detailed financial statements for Nevakar
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Nevakar
3 dated milestones of Nevakar across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Nevakar is founded.
- Funding First funding round of $11.5M.
- Funding Latest funding round, Series C, of $4.6M.
Competitors of Nevakar
Nevakar has 3 listed competitors in our database, 2 of them funded. They include Annexon, Aldeyra and Gyroscope.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| gyroscope.cc | 2016 | San Francisco, United States | Mobile SDK developed for app engagement and monetization strategies. |
Detailed competitors of Nevakar
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nevakar
The website of Nevakar (nevakar.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▼ 33.8% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as Nevakar (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nevakar
Complete news archive for Nevakar
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nevakar
Nevakar was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Nevakar is headquartered in New York, United States. It is registered at New York, New York, United States.
George Zorich is the CEO of Nevakar, as recorded in our data.
Nevakar is a funded company, having raised a total of $71.09M across 5 funding rounds to date. The company's 1st funding round was a Series A of $11.5M, raised on Jun 2016.
The primary company behind Nevakar, Nevakar India Private Limited, reported revenue of ₹1.77 Cr for FY 2025, down 21% year on year.
Nevakar was established in 2015 in New York, United States, within the pharmaceutical industry. Focus is placed on repositioning FDA-approved molecules to address unmet clinical and commercial needs. Operations involve the creation of novel formulations, improved packaging designs, and alternative drug delivery methods, primarily for injectable and ophthalmic applications. The company is led by founder Navneet Puri and CEO George Zorich.
Nevakar offers NVK002.
Nevakar has 2 investors. Key investors include Oxford Finance, and H.I.G. Capital.
Nevakar operates through Nevakar India Private Limited.
The legal entities of Nevakar currently have 2 directors, including Partha Pratim Mandal, Rahul Agarwalla.